BREAKINGOpenAI launches GPT-5 • Apple Vision Pro 2 confirmed for September • NVIDIA Blackwell Ultra ships to cloud providers
Breaking
OpenAI GPT-5 launches with 87% human expert benchmark performanceZepto files DRHP for ₹5B IPO on BSE and NSE — Q3 listing likelyNVIDIA Blackwell Ultra begins shipping to AWS, Azure, Google CloudIndia UPI crosses 20 billion monthly transactions for first timeApple Vision Pro 2 confirmed for September 2026 — starting at $2,499Peak XV Partners closes $2.85B fund, largest India-focused VC fund everTesla FSD 13.0 rolls out to Cybertruck — 847 miles between interventionsSamsung Galaxy S26 Ultra to feature under-display front cameraOpenAI GPT-5 launches with 87% human expert benchmark performanceZepto files DRHP for ₹5B IPO on BSE and NSE — Q3 listing likelyNVIDIA Blackwell Ultra begins shipping to AWS, Azure, Google CloudIndia UPI crosses 20 billion monthly transactions for first timeApple Vision Pro 2 confirmed for September 2026 — starting at $2,499Peak XV Partners closes $2.85B fund, largest India-focused VC fund everTesla FSD 13.0 rolls out to Cybertruck — 847 miles between interventionsSamsung Galaxy S26 Ultra to feature under-display front camera

DeepMind AlphaFold 3 Achieves 99% Accuracy on Protein Structures, Unlocking New Drug Targets

Google DeepMind's AlphaFold 3 has achieved 99% accuracy on known protein structures and can now predict how proteins interact with small molecules.

DS
Dr. Supriya Rao
| 30 April 202630 April 2026
Share
DeepMind AlphaFold 3 Achieves 99% Accuracy on Protein Structures, Unlocking New Drug Targets

Google DeepMind has released AlphaFold 3, the latest version of its groundbreaking protein structure prediction system.

Scientific Achievement

AlphaFold 3 extends beyond protein folding to model the full molecular biology of life, including DNA, RNA, and small molecule ligands.

Drug Discovery Applications

Several pharmaceutical companies have already begun using AlphaFold 3 in their drug development pipelines. Novartis reports using the system to identify 3 potential drug candidates for a rare genetic disorder in 6 months.

Open Access

AlphaFold 3 is available through a research portal with free academic access and commercial licensing.